公开(公告)号：US10117858B2

公开(公告)日：2018-11-06

申请号：US15156528

申请日：2016-05-17

Applicant: Novartis AG

Inventor： Urs Baettig ,  Kamlesh Bala ,  Emma Budd ,  Lee Edwards ,  Catherine Howsham ,  Glyn Alan Hughes ,  Darren Mark LeGrand ,  Katrin Spiegel

IPC: A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4412 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/4418 ,  C07D213/81 ,  C07D241/28 ,  C07D401/04 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D213/38 ,  C07D401/12 ,  C07D403/12 ,  C07D405/04 ,  C07D241/26

Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.

公开(公告)号：US09365552B2

公开(公告)日：2016-06-14

申请号：US14521843

申请日：2014-10-23

Applicant: Novartis AG

Inventor： Urs Baettig ,  Kamlesh Bala ,  Emma Budd ,  Lee Edwards ,  Catherine Howsham ,  Glyn Alan Hughes ,  Darren Mark Legrand ,  Katrin Spiegel

IPC: A61K31/44 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/5377 ,  A61K31/4418 ,  A61K45/06 ,  C07D405/04 ,  C07D213/81 ,  C07D241/28 ,  C07D401/04 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12 ,  C07D213/38 ,  C07D401/12 ,  C07D403/12 ,  A61K31/4412

CPC classification number: A61K31/44 ,  A61K31/4412 ,  A61K31/4418 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/497 ,  A61K31/5377 ,  A61K45/06 ,  C07D213/38 ,  C07D213/81 ,  C07D241/26 ,  C07D241/28 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D413/04 ,  C07D413/12

Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.